• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Marillyn Hewson Joins Chevron’s Board of Directors

    12/2/20 4:30:00 PM ET
    $JNJ
    $CVX
    $LMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Integrated oil Companies
    Energy
    Get the next $JNJ alert in real time by email

    SAN RAMON, Calif.--(BUSINESS WIRE)--Chevron Corporation (NYSE: CVX) announced that Marillyn A. Hewson has been elected to Chevron’s board of directors, effective on January 1, 2021. She will serve on the Audit Committee of the Board.

    Hewson, 66, is executive chairman of Lockheed Martin Corporation. She served as Lockheed Martin’s chairman, president and chief executive officer from January 2014 to June 2020 and held the positions of president and chief executive officer from January 2013 to December 2013.

    “It’s truly an honor to welcome Marillyn to Chevron’s board,” said Chevron Chairman and CEO Michael Wirth. “Marillyn is one of the world’s most accomplished business leaders. She brings valuable global business experience as well as decades of perspective on international commerce and geopolitics to our board, and will make our company better.”

    Hewson joined Lockheed Martin more than 35 years ago as an industrial engineer. During her career she has held leadership positions across the corporation. She currently serves on the board of directors of Johnson & Johnson, the Congressional Medal of Honor Foundation, the Board of Governors of the USO, and as chair of the Catalyst Board of Directors. Hewson has served on several U.S. government advisory bodies, including her current appointment to the American Workforce Policy Advisory Board. She earned her Bachelor of Science degree in business administration and her Master of Arts degree in economics from The University of Alabama and has completed executive development programs at Columbia Business School and Harvard Business School.

    Chevron Corporation is one of the world’s leading integrated energy companies. Through its subsidiaries that conduct business worldwide, the company is involved in virtually every facet of the energy industry. Chevron explores for, produces and transports crude oil and natural gas; refines, markets and distributes transportation fuels and lubricants; manufactures and sells petrochemicals and additives; generates power; and develops and deploys technologies that enhance business value in every aspect of the company’s operations. Chevron is based in San Ramon, Calif. More information about Chevron is available at www.chevron.com.

    Get the next $JNJ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ
    $CVX
    $LMT

    CompanyDatePrice TargetRatingAnalyst
    Chevron Corporation
    $CVX
    2/17/2026$205.00Hold → Buy
    Melius
    Lockheed Martin Corporation
    $LMT
    2/3/2026$665.00Buy → Hold
    DZ Bank
    Chevron Corporation
    $CVX
    2/2/2026$160.00 → $168.00Hold
    TD Cowen
    Chevron Corporation
    $CVX
    2/2/2026$180.00Buy → Hold
    HSBC Securities
    Johnson & Johnson
    $JNJ
    1/28/2026$262.00Equal-Weight → Overweight
    Morgan Stanley
    Chevron Corporation
    $CVX
    1/20/2026$176.00Neutral → Overweight
    Analyst
    Lockheed Martin Corporation
    $LMT
    1/9/2026$605.00Hold → Buy
    Truist
    Lockheed Martin Corporation
    $LMT
    12/19/2025$515.00Overweight → Neutral
    Analyst
    More analyst ratings

    $JNJ
    $CVX
    $LMT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $CVX
    $LMT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

    More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension study, showing lasting disease control for patients  78% of patients achieved intestinal healing at both the tissue and visual level (histo-endoscopic mucosal improvement)STOCKHOLM, Feb. 21, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA® (guselkumab) sustained clinical, endoscopic, and histologic outcomes through Week 140 in adults with moderately to severely active ulcerative colitis (UC). These data are among the 30 compa

    2/21/26 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

    Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO™; results surpass current standards of careRARITAN, N.J., Feb. 19, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma (HNSCC) that is recurrent or metastatic, PD-L1-positive, and human papillomavirus (HPV)-unrelated. Data were presented during a plenary session at the 2026 Multid

    2/19/26 5:00:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

    Advanced manufacturing site will utilize cutting‑edge cell therapy technologies to help deliver the company's portfolio of transformational medicines Facility will boost Pennsylvania's economy by creating more than 4,000 construction jobs and 500 biomanufacturing jobs, while further strengthening the Company's annual $10 billion economic impact across the state Investment is part of Company's $55 billion U.S. investment by early 2029 and supports plans to manufacture the vast majority of its advanced medicines in the U.S. to meet the needs of patients in the U.S. Johnson & Johnson (NYSE:JNJ) (the "Company"), healthcare's leading, most comprehensive innovation powerhouse, today ann

    2/18/26 10:15:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $CVX
    $LMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/12/24 5:27:36 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $CVX
    $LMT
    SEC Filings

    View All

    SEC Form 13F-HR filed by Johnson & Johnson

    13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)

    2/13/26 4:24:01 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 13F-HR filed by Chevron Corporation

    13F-HR - CHEVRON CORP (0000093410) (Filer)

    2/12/26 4:26:08 PM ET
    $CVX
    Integrated oil Companies
    Energy

    SEC Form S-3ASR filed by Johnson & Johnson

    S-3ASR - JOHNSON & JOHNSON (0000200406) (Filer)

    2/11/26 5:24:20 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $CVX
    $LMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, DM&C Walz Andrew Benjamin sold $268,950 worth of shares (1,463 units at $183.83), closing all direct ownership in the company (SEC Form 4)

    4 - CHEVRON CORP (0000093410) (Issuer)

    2/20/26 4:46:46 PM ET
    $CVX
    Integrated oil Companies
    Energy

    Controller Knowles Alana K sold $441,327 worth of shares (2,408 units at $183.28), closing all direct ownership in the company (SEC Form 4)

    4 - CHEVRON CORP (0000093410) (Issuer)

    2/20/26 4:44:53 PM ET
    $CVX
    Integrated oil Companies
    Energy

    EVP, CIO Swanson James D. sold $15,109,759 worth of shares (62,080 units at $243.39), exercised 73,140 shares at a strike of $139.50 and covered exercise/tax liability with 4,213 shares, increasing direct ownership by 36% to 25,698 units (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    2/18/26 9:12:32 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $CVX
    $LMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chevron upgraded by Melius with a new price target

    Melius upgraded Chevron from Hold to Buy and set a new price target of $205.00

    2/17/26 7:31:07 AM ET
    $CVX
    Integrated oil Companies
    Energy

    Lockheed Martin downgraded by DZ Bank with a new price target

    DZ Bank downgraded Lockheed Martin from Buy to Hold and set a new price target of $665.00

    2/3/26 6:53:05 AM ET
    $LMT
    Military/Government/Technical
    Industrials

    TD Cowen reiterated coverage on Chevron with a new price target

    TD Cowen reiterated coverage of Chevron with a rating of Hold and set a new price target of $168.00 from $160.00 previously

    2/2/26 7:18:00 AM ET
    $CVX
    Integrated oil Companies
    Energy

    $JNJ
    $CVX
    $LMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    2/13/24 5:07:58 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Chevron Corporation (Amendment)

    SC 13G/A - CHEVRON CORP (0000093410) (Subject)

    2/13/24 4:55:53 PM ET
    $CVX
    Integrated oil Companies
    Energy

    $JNJ
    $CVX
    $LMT
    Leadership Updates

    Live Leadership Updates

    View All

    Chevron Announces Leadership Changes

    Alana K. Knowles to retire after 38 years with the company Amit R. Ghai named Controller of Chevron Chevron Corporation (NYSE:CVX) announced today the appointment of Amit R. Ghai as Controller of Chevron, effective March 1, 2026. Ghai will succeed Alana K. Knowles, in anticipation of her expected retirement from Chevron in April 2026, after 38 years of service. Ghai will lead Chevron's accounting policy, corporate and external financial reporting, internal controls, global business services and digital finance teams. He will report to Eimear Bonner, Chevron's Vice President and Chief Financial Officer. "Amit's broad financial background, effective leadership as assistant controller

    11/3/25 8:00:00 AM ET
    $CVX
    Integrated oil Companies
    Energy

    Global Threat Surge Leads to $2.7T Defense Spending Boom and Institutional Rush

    Equity Insider News Commentary Issued on behalf of VisionWave Holdings, Inc. VANCOUVER, BC, Sept. 26, 2025 /PRNewswire/ -- Global military spending hit a record $2.7 trillion in 2024, marking a 9.4% surge that represents the steepest year-over-year increase in at least three decades as nations respond to "intensifying wars and rising geopolitical tensions worldwide," according to UN report[1]. NATO's updated defense expenditure data released in August confirms all 32 allies are expected to meet the 2% GDP spending target this year, while the alliance's commitment to reach 5% of GDP by 2035 creates unprecedented demand for advanced military technologies and platforms[2]. This defense spending

    9/26/25 10:30:00 AM ET
    $GD
    $LHX
    $LMT
    Marine Transportation
    Industrials
    Industrial Machinery/Components
    Military/Government/Technical

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    $JNJ
    $CVX
    $LMT
    Financials

    Live finance-specific insights

    View All

    Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

    AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile), which holds multiple clinical-stage and late-stage program

    2/17/26 8:30:00 AM ET
    $ARWR
    $JNJ
    $MGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Lockheed Martin Declares First Quarter 2026 Dividend

    BETHESDA, Md., Feb. 6, 2026 /PRNewswire/ -- The Lockheed Martin Corporation (NYSE: LMT) board of directors has authorized a first quarter 2026 dividend of $3.45 per share. The dividend is payable on March 27, 2026, to holders of record as of the close of business on March 2, 2026. As stated in our most recent earnings release, Lockheed Martin is significantly increasing our investments while maintaining our historical practice of using a disciplined and dynamic approach to capital allocation.  About Lockheed MartinLockheed Martin is a global defense technology company driving

    2/6/26 4:52:00 PM ET
    $LMT
    Military/Government/Technical
    Industrials

    Chevron Reports Fourth Quarter 2025 Results

    Reported earnings of $2.8 billion; adjusted earnings of $3.0 billion Cash flow from operations of $10.8 billion; adjusted free cash flow of $4.2 billion Increased 2025 worldwide and U.S. production by 12 and 16 percent to record levels Reserve replacement ratio of 158 percent in 2025 Announces a 4 percent increase in quarterly dividend to $1.78 per share Chevron Corporation (NYSE:CVX) reported earnings of $2.8 billion ($1.39 per share - diluted) for fourth quarter 2025, compared with $3.2 billion ($1.84 per share - diluted) in fourth quarter 2024. Included in the quarter was a net loss of $128 million due to pension settlement costs. Foreign currency effects decreased earnin

    1/30/26 6:15:00 AM ET
    $CVX
    Integrated oil Companies
    Energy